Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH)
- PMID: 29928018
- PMCID: PMC6013208
- DOI: 10.1371/journal.pone.0199294
Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH)
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and major cause of chronic liver disease in developed countries. Its prevalence is increasing in parallel with the prevalence of obesity and other components of the metabolic syndrome. As the liver is central to the clearance and catabolism of circulating advanced glycosylation end-products (AGEs), AGEs and their cognate receptors-RAGE (receptor for AGEs) system might be involved in NAFLD in obese patients. To examine this, we investigated four common polymorphisms of RAGE gene: 1704G/T (rs184003), G82S (rs2070600), -374T/A (rs1800624) and -429T/C (rs1800625) in 340 obese patients with metabolic syndrome. and protein levels of AGE and RAGE. This is the first study to describe association of 4 common polymorphisms with non-alcoholic steatohepatitis (NASH) as well as to examine protein levels of RAGE and AGE. Univariate analysis showed patients carrying the rs1800624 heterozygote genotype (AT) exhibited 2.36-fold increased risk of NASH (odds ratio (OR) = 2.36; 95% confidence interval (95% CI): 1.35-4.19) after adjusting for confounders. The minor allele -374 A has been shown to suppress the expression of RAGE protein. The protein levels of esRAGE, total sRAGE and AGE protein levels did not correlate with each other in obese patients with no liver disease, indicative of RAGE signaling playing an independent role in liver injury. In obese patients with non-NASH NAFLD and NASH respectively, esRAGE protein showed strong positive correlation with total sRAGE protein. Further, haplotype analysis of the 4 SNPs, indicated that haplotype G-A-T-G was significantly associated with 2-fold increased risk for NASH (OR = 2.08; 95% CI: 1.21-3.5; P = 0.006) after adjusting for confounders. In conclusion, the presented data indicate that the G-A-T-G haplotype containing minor allele at position -374 A and major allele at position -429T, 1704G, and G82S G could be regarded as a marker for NASH.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures

Similar articles
-
RAGE gene polymorphism and environmental factor in the risk of oral cancer.J Dent Res. 2015 Mar;94(3):403-11. doi: 10.1177/0022034514566215. Epub 2015 Jan 12. J Dent Res. 2015. PMID: 25582438 Free PMC article.
-
The promoter polymorphisms of receptor for advanced glycation end products were associated with the susceptibility and progression of sepsis.Clin Genet. 2017 Apr;91(4):564-575. doi: 10.1111/cge.12800. Epub 2016 Jun 30. Clin Genet. 2017. PMID: 27172264
-
Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population.J Cell Mol Med. 2016 Oct;20(10):1966-73. doi: 10.1111/jcmm.12888. Epub 2016 May 31. J Cell Mol Med. 2016. PMID: 27241711 Free PMC article.
-
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.World J Hepatol. 2014 Dec 27;6(12):880-93. doi: 10.4254/wjh.v6.i12.880. World J Hepatol. 2014. PMID: 25544875 Free PMC article. Review.
-
A systematic review and meta-analysis of the relationship between advanced glycation end products ceceptor (RAGE) gene polymorphisms and the risk of inflammatory bowel disease.Caspian J Intern Med. 2023 Summer;14(3):412-424. doi: 10.22088/cjim.14.3.41. Caspian J Intern Med. 2023. PMID: 37520885 Free PMC article. Review.
Cited by
-
RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity.Cell Rep Med. 2023 Nov 21;4(11):101266. doi: 10.1016/j.xcrm.2023.101266. Epub 2023 Nov 8. Cell Rep Med. 2023. PMID: 37944530 Free PMC article.
-
Polymorphisms -374 T/A and -429 T/C of the Receptor for Advanced Glycation End-Products (RAGE) and Serum Levels of RAGE (sRAGE) Are Not Associated with Metabolic Syndrome.Metabolites. 2023 Apr 5;13(4):521. doi: 10.3390/metabo13040521. Metabolites. 2023. PMID: 37110179 Free PMC article.
-
Advanced Glycation End Products in Disease Development and Potential Interventions.Antioxidants (Basel). 2025 Apr 18;14(4):492. doi: 10.3390/antiox14040492. Antioxidants (Basel). 2025. PMID: 40298887 Free PMC article. Review.
-
Advanced Glycation End-Products in Common Non-Infectious Liver Diseases: Systematic Review and Meta-Analysis.Nutrients. 2021 Sep 25;13(10):3370. doi: 10.3390/nu13103370. Nutrients. 2021. PMID: 34684371 Free PMC article.
-
Indole-4-carboxaldehyde Isolated from Seaweed, Sargassum thunbergii, Attenuates Methylglyoxal-Induced Hepatic Inflammation.Mar Drugs. 2019 Aug 21;17(9):486. doi: 10.3390/md17090486. Mar Drugs. 2019. PMID: 31438528 Free PMC article.
References
-
- Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver. 2017;37 Suppl 1: 81–84. doi: 10.1111/liv.13299 - DOI - PubMed
-
- Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15: 45 doi: 10.1186/s12916-017-0806-8 - DOI - PMC - PubMed
-
- Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75: 721–728. - PubMed
-
- Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53: 1874–1882. doi: 10.1002/hep.24268 - DOI - PubMed
-
- Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatol Baltim Md. 1995;22: 1714–1719. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials